Genmab — Januar 2024
-
-
Pfizer skriver at FDA har accepteret Tivdak sBLA ansøgning om konvertering fra "accelerated approval" til fuld godkendelse med priority review og PDUFA dato d. 9 maj, se link side 8. 2024.https://s28.q4cdn.com/781576035/files/doc_financials/2023/q4/Q4-2023-PFE-Earnings-Release.pdf
-
Svar fra Andrew Carlsen angående stilleperioden "Our quiet period before earnings is still 2 weeks and has not been extended to 4 weeks with the US listing."
-
You are welcome.
-
Egentlig en meget subtil måde at spørge “hvad f#€&”€en i h#€”&€&€lvede foregår der!?”
-
The third Pfizer product to hit the reject pile is PF-07260437, a phase 1 therapy designed to treat advanced breast cancer, ovarian cancer or endometrial cancer. The B7-H4 x CD3 bispecific monoclonal antibody was being tested among 30 patients in a study that wrapped in October of last year, as listed on ClinicalTrials.gov.
-
-
This decision was not due to major safety concerns (fra Clinical Trials)https://classic.clinicaltrials.gov/ct2/show/NCT05067972
-
Godmorgen
-
Dagens regnskaber: https://www.proinvestor.com/finanskalender
-
Ja lød semi optimistisk på JP Morgan omkring dette - men fremhævede jo også problemer for både T-cell engagers og CAR-T i solide tumorer, så det er jo allerde svært. Omvendt er de igennem dosis opskalering og nu i gang med expansion - og Jan sagde at safety var ok og de havde set tegn på effekt.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind